A Phase 2 interventional study of sitamaquine in Leishmaniasis, Visceral, sponsored by GlaxoSmithKline. Completed at 3 sites in India. Open to participants aged 16 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-09-18.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Sitamaquine is an 8-aminoquinoline which is being developed as an oral treatment for visceral leishmaniasis (VL). Pre-clinical and subsequent clinical investigations have demonstrated oral efficacy against Leishmania donovani. The purposes of this study are to characterise the pharmacokinetic profile of sitamaquine, administered orally, and to determine if the pharmacokinetic profile is affected by administration with food. The study is also designed to further characterise the safety and tolerability of sitamaquine compared with amphotericin B, particularly in reference to renal, hepatic and cardiac adverse events, prior to initiation of phase III studies. Finally the study will investigate the efficacy of a 21 day treatment course. Previous studies have used 28 days dosing, but parasitological evidence from one study suggests that shorter courses may be effective.
185 studies on the registry are indexed under Leishmaniasis; 15 are open to participants now.
This study's enrollment of 61 is below the median of 80 across 133 interventional studies indexed under Leishmaniasis.
Browse Leishmaniasis studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
Subjects suffering from a concomitant infection, blood disorder or any other serious underlying disease which would preclude evaluation of the subject's response to the study medication.
Methaemoglobin levels >5% at screening. G6PD deficiency.
Area under the concentration-time curve over the dosing interval AUC(0-tau) for sitamaquine
AUC is defined as the area under the concentration-time curve from 0 to last quantifiable concentration (AUC 0-tau). AUC is a measure of exposure. Blood samples for determination of plasma concentrations of sitamaquine was obtained at the following time points on days 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose. An additional sample was taken on Day 23 and Day 24 to approximate 48 hours and 72 hours post last dose on Day 21. Only those participants with data available at the specified time points were analyzed.
Time frame: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose
Maximum plasma concentration (Cmax) for sitamaquine
Cmax was defined as the maximum concentration of sitamaquine. Blood samples for determination of plasma concentrations of sitamaquine was obtained at the following time points on days 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours. An additional sample was taken on Day 23 and Day 24 to approximate 48 hours and 72 hours post last dose on Day 21.
Time frame: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose.
Time to maximum observed plasma concentration (tmax) for sitamaquine
Tmax is defined as the time to peak concentration from initiation of sitamaquine dosing. Blood samples for determination of plasma concentrations of sitamaquine was obtained at the following time points on days 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose. An additional sample was taken on Day 23 and Day 24 to approximate 48 hours and 72 hours post last dose on Day 21.
Time frame: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose.
Accumulation ratio for sitamaquine
Point estimate was the ratio of adjusted geometric means between repeat dosing days (Day 21 or Day 10) and single dose day (Day 1). An evaluation on the accumulation rate was based upon the comparison of AUC(0-24) values after repeated dosing to the values from the first dose on day 1. Blood samples for determination of plasma concentrations of sitamaquine was obtained at the following time points on days 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose. An additional sample was taken on Day 23 and Day 24 to approximate 48 hours and 72 hours post last dose on Day 21. Individual observed accumulation ratios on Day 10 were calculated by dividing AUC (0-tau) on Day 10 by AUC (0-tau) on Day 1. A similar formula was applied to the accumulation ratio on Day 21.
Time frame: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose
Number of participants with adverse events(AEs) and serious adverse events(SAEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Data for on-treatment AEs have been reported,
Time frame: Up to 180 days
Number of participants with abnormal 12-lead Electrocardiogram (ECG) values
Data for abnormal findings have been reported at Day 22 for Sitamaquine and Day 31 for Amphotericin B. All ECGs were collected in the supine position with the electrodes placed in the standard positions, 4 hours after dosing on drug administration days, and prior to blood collection or pulse rate measurement.
Time frame: At Day 22 for Sitamaquine and Day 31 for Amphotericin B
Number of participants with abnormal echocardiography results
2-D echocardiograms were performed at screening (all participants), Days 22 and 49 (sitamaquine only) and days 31 and 58 (amphotericin B only). All echocardiograms were obtained after the participant has rested in a semi-supine position for at least 10 minutes. All echocardiograms were stored electronically (e.g video home system \[VHS\] tape, optical drive, etc.). Ejection fraction was estimated using the modified Simpson's rule method. Data for number of participants with abnormal echocardiography results have been reported.
Time frame: Up to Day 22 and 49 (sitamaquine only) and Day 31 and 58 (amphotericin B only)
Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Day 180
Blood pressure (SBP and DBP) was recorded after the participant had rested in a semi-supine position for at least 10 minutes. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was Day 1 pre-dose.
Time frame: Baseline (Day 1 pre-dose) and Day 180
Change from Baseline in heart rate
Heart rate was recorded after the participant had rested in a semi-supine position for at least 10 minutes. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was Day 1 pre-dose.
Time frame: Baseline (Day 1 pre-dose) and Day 180
Change from Baseline in body temperature
Body temperature was recorded after the participant had rested in a semi-supine position for at least 10 minutes. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was Day 1 pre-dose.
Time frame: Baseline (Day 1 pre-dose) and Day 180
Change from Baseline in body weight
Body weight was recorded after the participant had rested in a semi-supine position for at least 10 minutes. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was Day 1 pre-dose.
Time frame: Baseline (Day 1 pre-dose) and Day 49 for Sitamaquine and Day 58 for Amphotericin B
Number of participants with abnormal hematology values at the end of study (Day 180)
Data for number of participants with hematology abnormalities for the end of study (Day 180) is presented. Hematology abnormalities were classified using Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Grades and grade 3 ranges are as follows (selected): Hemoglobin (grams per liter \[G/L\])- \<80 - 65; Total Neutrophils (gram international units per liter\[GI/L\])- \<1.0 - 0.5 x 10\^9/L; Platelet count(GI/L) \<50.0- 25.0 x 10\^9 /L; White Blood Cell (WBC) (GI/L)- \<2.0 - 1.0 x 10\^9 /L. Data only for categories with values have been presented.
Time frame: Day 180
Number of participants with abnormal clinical chemistry values at the end of study (Day 180)
Aspartate Amino Transferase (AST) (\[international units per liter \[IU/L\])- \>5.0 - 20.0 x upper limit of normal (ULN); Albumin(G/L)- \<20 g/dL; Alkaline Phosphatase(IU/L)- \>5.0 - 20.0 x ULN; Alanine Amino Transferase(IU/L)- \>5.0 - 20.0 x ULN; Total Bilirubin( micromoles per liter \[µMOL/L\])- \>3.0 - 10.0 x ULN; Urea(millimoles per liter \[MMOL/L\])- 5.1 - 10 x ULN; Cholesterol (MMOL/L) - \>10.34 - 12.92; Creatine Kinase MB (microgram per liter\[µ/L\])-\>5 x ULN - 10 x ULN; Creatinine Clearance(milliliter per minute \[mL/min\])- \<25% lower limit of normal (LLN); Creatinine(µMOL/L)- \>3.0 - 6.0 x ULN; Gamma Glutamyl Transferase(IU/L)- \>5.0 - 20.0 x ULN; Potassium(MMOL/L)- \>6.0 - 7.0(high) and \<3.0 - 2.5 (low); Sodium(MMOL/L)- \>155 - 160; Sodium(MMOL/L)- \<130 - 120; Triglycerides(MMOL/L)- \>5.0 - 10.0 x ULN. Data only for categories with values have been presented.
Time frame: Day 180
Number of participants with Initial parasitological cure (28 days)
Initial parasitological cure was defined as a parasite-negative splenic aspirate at completion of treatment or, if the leishmania index (a quantitative assessment of parasites in the splenic aspirate) was +1, a parasite-negative result at the repeat splenic aspirate 28 days later.
Time frame: Up to 28 days
Number of participants with Final parasitological cure (6 months)
Final clinical cure was defined as initial parasitological cure (initial parasitological cure was defined as a parasite-negative splenic aspirate at completion of treatment or, if the leishmania index \[a quantitative assessment of parasites in the splenic aspirate\] was +1, a parasite-negative result at the repeat splenic aspirate 28 days later) and no evidence of relapse at 6 months.
Time frame: Up to 180 days
Terminal elimination half-life (t1/2) for sitamaquine
Half life is defined as the period of time required for the amount of drug in the body to be reduced by half. Blood samples for determination of plasma concentrations of sitamaquine was obtained at the following time points on days 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose. An additional sample was taken on Day 23 and Day 24 to approximate 48 hours and 72 hours post last dose on Day 21.
Time frame: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline